In a recently published study, Norwegian scientists have identified specific markers and analytical methods that can predict whether a particular chemotherapy regimen for Acute myeloid leukemia (AML) will work for a particular patient within 24 hours. Previously it took months to determine if the chemotherapy treatment worked or not. AML is a common type of blood and bone marrow cancer and it usually gets worse quickly if it is not treated. Thus this study will allow doctors to find the right chemotherapy regimen in much less time. Eventually this will lead to better survival of patients with poor prognosis and will facilitate patient specific cancer treatment. The scientists hopes this method can be used for different types of leukemia and also can be re-purposed for other cancers.
Further reading -
Early response evaluation by single cell signaling profiling in acute myeloid leukemia
Tislevoll BS, Hellesøy M, Fagerholt OHE, Gullaksen SE, Srivastava A, Birkeland E, Kleftogiannis D, Ayuda-Durán P, Piechaczyk L, Tadele DS, Skavland J, Panagiotis B, Hovland R, Andresen V, Seternes OM, Tvedt THA, Aghaeepour N, Gavasso S, Porkka K, Jonassen I, Fløisand Y, Enserink J, Blaser N, Gjertsen BT. Nat Commun. 2023 Jan 7;14(1):115. doi: 10.1038/s41467-022-35624-4.PMID: 36611026